Study of oral cabazitaxel for advanced prostate cancer
Part of Cancer clinical trials.
This study tests an oral form of the chemotherapy drug cabazitaxel at different doses for men with prostate cancer that has spread and has progressed after prior docetaxel treatment. The goal is to see which dose works best and is safest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced prostate cancer that has spread to other parts of your body.
- You must have already been treated with docetaxel (a chemotherapy) for your prostate cancer.
- You must be on hormone therapy that keeps your testosterone very low (either medication or surgically).
- You must be able to carry out normal daily activities (performance status 0-2).
- You must be at least 18 years old and in generally good health apart from your prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
Hear when a new Metastatic Castration-resistant Prostate Cancer, MCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.